Expand Manufacturing Capacity

3 Suites

T.O. (rFVIII)

T.O. (rFVIII)

T.O. (rFVIII)

Neuchatel (rFVIII)

Neuchatel (rFVIII)

Neuchatel (rFVIII and/or Other Proteins)

6 Suites

9 Suites

Each suite will have over 2X the capacity as current T.O. suites

• Larger bioreactors

• Flexible production

Expected Recombinant Suite Utilization

Previous slide

Next slide

Back to first slide

View graphic version